ArticleEcancermedicalscience2024
Pericardial synovial sarcoma in a young adult: case report of a rare malignancy.
Article in Ecancermedicalscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synovial sarcoma is a rare mesenchymal tumour that mainly presents in adolescents and adults younger than 30. It is characterised by a translocation between chromosomes X and 18, which leads to the expression of SS18:SSX fusion proteins. Although it can arise from various soft tissues, the lower limb is the most common site of origin. Pericardial synovial sarcoma is an extremely rare primary malignant tumour of the heart with an unclear prognosis. There are only a few cases reported from Pakistan. Here, we report a case of a 33-year-old male who presented with symptoms of chest pain and shortness of breath. The case was discussed in a multi-disciplinary tumour board and the surgeons deferred surgery as it was associated with high-risk mortality and was also refused by the patient so he was first managed with systemic chemotherapy to which he responded very well and was shifted to maintenance therapy using Pazopanib (small molecule tyrosine kinase inhibitors), to which he initially responded but later symptoms started to worsen and there was an interval increase in the size of the lesion. This report aims to share the diagnosis and management of this patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.